The Nonhuman Primate (NHP) Core seeks to consolidate the NHP experimental objectives of the Consortia for AIDS Vaccine Research (CAVR) in Nonhuman Primates proposal into a single Core composed of highly experienced research personnel. This Core will provide the expertise and technical support required to insure successful completion of the multifaceted and extensive NHP research protocols supporting Project 1 - "Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection", Project 2 - "CMV Vectors and Early Control of Mucosal SIV Challenge", Project 3 - "Live Attenuated SIV-Mediated Protection Against Mucosal SIV Infection", Project 4 - "Mechanisms of Antibody Interception of Virus Following SHIV Challenge" and Project 5 - "Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection". These projects constitute a collaborative, interactive, and comprehensive investigation of acute mucosal SIV infection and the systematic evaluation of vaccines and which immune responses can block or modulate these early events of SIV infection to prevent infection or disease. The global objective of the Core is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, application of experimental animal procedures, animal observations and data collection necessary to meet the comprehensive investigation objectives of the CAVR.'s To accomplish this, the Core will manage and directly supervise all NHP studies for the CAVR including: 1) animal selection;2) animal housing and general husbandry;3) experimental procedures and clinical management;4) specimen collection and processing;5) necropsy studies;and 6) acquisition and management of animal demographic, physiologic, clinical, and pathologic data.
NHP research is expensive, and requires highly specialized resources and personnel. Consolidation of multiple interactive projects into a integrative multdicipline core had decided advantages in correlation of results, efficient animals handling and speciment process, use of fewer animals and efficient use of animals facility space and resources.
|Stephenson, Kathryn E; Neubauer, George H; Reimer, Ulf et al. (2015) Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods 416:105-23|
|Barouch, Dan H; Picker, Louis J (2014) Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12:765-71|
|Dugast, Anne-Sophie; Chan, Ying; Hoffner, Michelle et al. (2014) Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One 9:e97229|
|Balandya, Emmanuel; Miller, Andrew D; Beck, Matthew et al. (2014) Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys. J Virol 88:3756-65|
|Barouch, Dan H; Michael, Nelson L (2014) Accelerating HIV-1 Vaccine Efficacy Trials. Cell 159:969-72|
|Li, Qingsheng; Zeng, Ming; Duan, Lijie et al. (2014) Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 193:3113-25|
|Whitney, James B; Hill, Alison L; Sanisetty, Srisowmya et al. (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512:74-7|
|Teigler, Jeffrey E; Phogat, Sanjay; Franchini, Genoveffa et al. (2014) The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 88:1809-14|
|Shang, Liang; Smith, Anthony J; Duan, Lijie et al. (2014) NK cell responses to simian immunodeficiency virus vaginal exposure in naive and vaccinated rhesus macaques. J Immunol 193:277-84|
|Barouch, Dan H; Deeks, Steven G (2014) Immunologic strategies for HIV-1 remission and eradication. Science 345:169-74|
Showing the most recent 10 out of 20 publications